Colorectal Cancer

Andrea Cercek, MD, discusses the importance of molecular testing in colorectal cancer.

Benjamin Weinberg, MD, discusses the role of cetuximab in treating metastatic colorectal cancer.

Girish Putcha, MD, PhD, discusses the use of blood-based screening assays in colorectal cancer (CRC).

Third-line treatment of patients with metastatic colorectal cancer using regorafenib plus oral fluoropyrimidine TAS-102 provides clinically meaningful disease control with toxicities consistent with the safety profiles of either agent, according to data from the phase I dose-escalation trial REMETY presented at the 2020 Gastrointestinal Cancers Symposium.

A regimen of avelumab and cetuximab plus oxaliplatin, leucovorin, and 5-fluorouracil in patients with RAS/BRAF-wildtype metastatic colorectal cancer induced a very high response rate but did not meet its primary progression-free survival end point.

Scott Kopetz, MD, PhD, FACP, sheds light on encorafenib triplet and doublet options for patients with BRAF V600E–mutant metastatic colorectal cancer and other novel regimens under investigation.

Van Morris, MD, discusses research around treatment for patients with unresectable colorectal cancer.

Investigators hope to answer a potentially paradigm-changing question in the phase II ANCHOR-CRC study (NCT03693170) of BRAF V600E–mutant colorectal cancer (CRC): Can the benefit observed with a targeted triplet in latestage disease extend to the first line?

Between 2013 and 2017, just 40% of patients with metastatic colon cancer received guideline-recommended biomarker testing that could have improved treatment decisions, according to findings from a retrospective study. Results also showed that adherence to evidence-based recommendations for genotyping was poor in academic and community settings alike.

A. Craig Lockhart, MD, MHS, professor and associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses investigational strategies targeting the RAS/RAF/MEK/ERK pathway in colorectal cancer (CRC).

The standard of care in the second line for patients with mismatch repair–deficient metastatic colorectal cancer has shifted to favor therapy utilizing immunotherapeutic agents, according to Howard Hochster, MD.

A. Craig Lockhart, MD, MHS, discusses ongoing developments and the future of immunotherapy in colorectal cancer.

Benjamin Weinberg, MD, discusses varying treatment options for patients with metastatic colorectal cancer.